Influence of Delayed Initiation of Cyclosporine on Everolimus Pharmacokinetics in de Novo Renal Transplant Patients-Reference-Cited by-同舟云学术

Influence of Delayed Initiation of Cyclosporine on Everolimus Pharmacokinetics in de Novo Renal Transplant Patients

Published:2003-10-06 Issue:12 Volume:3 Page:1576-1580
ISSN:1600-6135
Container-title:American Journal of Transplantation
language:en
Short-container-title:

Author:

Kovarik John M.,Dantal Jacques,Civati Giovanni,Rizzo Gaetano,Rouilly Marisel,Bettoni-Ristic Olga,Rordorf Christiane

Publisher

Wiley

Subject

Pharmacology (medical),Transplantation,Immunology and Allergy

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1600-6135.2003.00242.x/fullpdf

Reference10 articles.

1. SDZ RAD, a new rapamycin derivative;Schuler;Transplantation,1997

2. Review of proliferation inhibitor everolimus;Nashan;Expert Opin Invest Drugs,2002

3. 12-month results of a multicenter study comparing efficacy and safety of everolimus to azathioprine in de novo cardiac transplantation;Valantine;Am J Transplant,2002

4. Phase 1 study of a 4-week course of SDZ-RAD in quiescent cyclosporine-prednisone-treated renal transplant recipients;Kahan;Transplantation,1999

5. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation;Kovarik;Am J Transplant,2003

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ten-Year Follow-up of Pharmacokinetics-Guided Very Early Cyclosporine Minimization Synchronized With Everolimus Initiation in De Novo Kidney Transplantation;Transplantation Proceedings;2017-10

2. Calcineurin inhibitor withdrawal or tapering for kidney transplant recipients;Cochrane Database of Systematic Reviews;2017-07-21

3. Current methods of the analysis of immunosuppressive agents in clinical materials: A review;Journal of Pharmaceutical and Biomedical Analysis;2016-08

4. Effect of confounding factors on a phospho-flow assay of ribosomal S6 protein for therapeutic drug monitoring of the mTOR-inhibitor everolimus in heart transplanted patients;Biomarkers;2016-07-22

5. Three-year results of an investigator-driven multicenter, international, randomized open-label de novo trial to prevent BOS after lung transplantation;The Journal of Heart and Lung Transplantation;2015-01